Wall Street analysts expect that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) will announce ($0.51) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Ionis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.69). Ionis Pharmaceuticals reported earnings per share of ($0.23) in the same quarter last year, which would suggest a negative year over year growth rate of 121.7%. The company is expected to announce its next quarterly earnings results on Wednesday, August 4th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full-year earnings of ($1.70) per share for the current financial year, with EPS estimates ranging from ($1.94) to ($1.51). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.45) per share, with EPS estimates ranging from ($2.30) to ($0.28). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, May 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.16). The firm had revenue of $112.00 million during the quarter, compared to the consensus estimate of $134.93 million. Ionis Pharmaceuticals had a negative return on equity of 41.74% and a negative net margin of 69.63%. The firm’s revenue was down 15.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.35) EPS.
NASDAQ:IONS traded up $1.29 on Thursday, hitting $38.21. The stock had a trading volume of 2,579,249 shares, compared to its average volume of 1,488,690. The company’s fifty day moving average price is $39.57. The company has a market cap of $5.39 billion, a P/E ratio of -10.46 and a beta of 1.09. The company has a debt-to-equity ratio of 1.28, a quick ratio of 6.67 and a current ratio of 6.74. Ionis Pharmaceuticals has a 52 week low of $34.43 and a 52 week high of $64.37.
A number of large investors have recently added to or reduced their stakes in IONS. International Assets Investment Management LLC purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $26,000. Harbour Investments Inc. purchased a new stake in Ionis Pharmaceuticals in the first quarter worth $27,000. Childress Capital Advisors LLC purchased a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at $31,000. Total Clarity Wealth Management Inc. purchased a new position in shares of Ionis Pharmaceuticals in the first quarter valued at $31,000. Finally, Allred Capital Management LLC purchased a new position in shares of Ionis Pharmaceuticals in the first quarter valued at $35,000. 86.17% of the stock is owned by institutional investors and hedge funds.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
Featured Story: Call Option Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.